Unknown

Dataset Information

Long-term safety of vedolizumab for inflammatory bowel disease.


ABSTRACT:

Background

Vedolizumab, a gut-selective α4 β7 integrin antibody, is approved for moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

Aim

To report the final results from the vedolizumab GEMINI long-term safety (LTS) study.

Methods

The phase 3, open-label GEMINI LTS study (initiated May 2009) enrolled patients with UC or CD from four prior clinical trials and vedolizumab-naïve patients. Vedolizumab LTS was evaluated; efficacy and patient-reported outcomes were exploratory endpoints.

Results

Enrolled patients (UC, n = 894; CD, n = 1349) received vedolizumab 300 mg IV every 4 weeks; median cumulative exposure was 42.4 months (range: 0.03-112.2) for UC and 31.5 months (range: 0.03-100.3) for CD. Over 8 years, advers

SUBMITTER: Loftus EV 

PROVIDER: S-EPMC7540482 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature